Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Legal barriers are preventing generic drug makers from being able to utilize the Patent Trial and Appeal Board for its intended purpose — to serve as a faster and less cumbersome alternative to district court litigation.
Academia and the pharmaceutical industry must unite to offer more comprehensive opportunities for those wanting to stay in research in the field of drug development.
Nature Biotechnology’s annual survey highlights academic startups that are, among other things, designing circular RNA therapeutics, tackling cancer with arenaviruses, creating psychedelics without the trip, editing genes and cells in vivo, harnessing the power of autoantibodies and editing the epigenome.
Researchers are designing diets that may improve patient responses to cancer therapy by using machine learning and genotyping to uncover tumors’ nutritional vulnerabilities.
Developing a device development educational core will further enhance national, international and multidisciplinary innovation and collaboration in the biomedical device domain.